Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine

Leukemia

Volumn 25, Issue 7, 2011, Pages 1207-1209

  Itzykson, R ^a   Thepot S ^a   Eclache, V ^a   Quesnel, B ^b   Dreyfus, F ^c   Beyne Rauzy, O ^d   Turlure, P ^e   Vey, N ^f   Recher, C ^d   Boehrer, S ^a   Gardin, C ^a   Ades L ^a   Fenaux, P ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c AP HP   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

^f INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHROMOSOME ABERRATION; FOLLOW UP; HIGH RISK PATIENT; HUMAN; KARYOTYPE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SCORING SYSTEM;

ANTIMETABOLITES; AZACITIDINE; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, PAIR 7; COMPASSIONATE USE TRIALS; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; KARYOTYPING; MONOSOMY; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 79960207573     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.63     Document Type: Article

References (7)

1. Patnaik MM, Hanson CA, Hodnefield JM, Knudson R, Van Dyke DL, Tefferi A. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia 2011; 25: 266-270.
2. Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26: 4791-4797.
3. Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood 2010; 116: 2224-2228.
4. Kantarjian HM, O0Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007; 109: 265-273. (Pubitemid 46106241)
5. Mufti GJ, Gore SD, Santini V, Fenaux P, Silverman LR, Hagemeijer A et al. Influence of karyotype on overall survival in patients with higher-risk myelodysplastic syndrome treated with azacitidine or a conventional care regimen. Blood (ASH Ann Meet) 2009, pp 1755.
6. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
7. Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P et al. Prognostic factors of response and overall survival in higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011; 117: 403-411.